Stryker (1SYK) Stock Price & Analysis
1SYK Stock Chart & Stats
- Day’s Range
- EUR 264.50 - EUR 266.50
- 52-Week Range
- EUR 151.00 - EUR 490.00
- Previous Close
- EUR 279.40
- Volume
- 130
- Average Volume (3M)
- 6
- Market Cap
- EUR 99.90B
- Enterprise Value
- EUR 118.10B
- Total Cash (Recent Filing)
- EUR 3.27B
- Total Debt (Recent Filing)
- EUR 15.43B
- Price to Earnings (P/E)
- 30.9
- Beta
- 0.29
- Next Earnings
- Feb 02, 2027 (Est.)
- EPS Estimate
- 4.49
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.17%
Bulls Say, Bears Say
Bulls Say
Organic Growth And Diversified Demand
Stryker is continuing to expand across multiple medical technology categories, reducing reliance on any single product line or procedure type. Broad organic growth, particularly in MedSurg and Neurotechnology, supports durable market-share gains and provides a stronger base for sustained revenue compounding.
Strong Margins And Profitability
High gross and operating margins indicate meaningful product differentiation, pricing power, and operating scale in Stryker’s core businesses. Margin expansion from operational efficiencies and expense discipline can support earnings growth, fund innovation, and improve resilience through variable procedure environments.
Innovation And Portfolio Expansion
Stryker is extending its addressable market through acquisitions, robotics, and new surgical technologies rather than relying solely on existing implants. This active innovation and M&A strategy can strengthen customer relationships, broaden the portfolio, and create additional long-term growth avenues.
Bears Say
Hip And Knee Slowdown
Slower hip and knee procedure growth directly limits demand for important orthopaedic products and may keep the segment near market growth instead of its historical outperformance. Affordability concerns, pre-authorization denials, and regional softness could prolong pressure over the next several quarters.
Orthopaedics Execution Challenges
Execution issues make the orthopaedics weakness more significant than an industry slowdown alone. Disruption from the cyber incident and SAP implementation, combined with slower new-product adoption, could delay recovery, weaken competitive momentum, and constrain near-term growth in a major franchise.
Supply And Guidance Pressure
The reduced outlook signals that operational and market challenges are affecting the company’s near-term growth trajectory. Lingering vascular supply constraints and weaker orthopaedic trends may pressure revenue conversion, while a lower forecast reduces visibility into the pace of earnings progression.
1SYK FAQ
What was Stryker’s price range in the past 12 months?
What is Stryker’s market cap?
When is Stryker’s upcoming earnings report date?
How were Stryker’s earnings last quarter?
Is Stryker overvalued?
Does Stryker pay dividends?
What is Stryker’s EPS estimate?
How many shares outstanding does Stryker have?
What happened to Stryker’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stryker?
What is the TipRanks Smart Score and how is it calculated?
Stryker Stock Smart Score
Company Description
Stryker
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo
- Employees
- 56,000
- Website
- www.stryker.com
- Address
- 1941 Stryker Way, Portage, MI, 49002, US
Stryker (1SYK) Earnings & Revenues
1SYK Earnings Call
Earnings Call SentimentNeutral
The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.
View all IT:1SYK earnings summaries1SYK Net sales Breakdown
- 62.30% MedSurg and Neurotechnology
- 37.70% Orthopaedics and Spine
1SYK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 5 | 11 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 4 | 0 | 8 |